Econazole
As of the edition of 20 October 2026, Econazole is a small molecule: marketed, first approved in 1978 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Spectazole
- First approved
- 3 August 1978 (FR)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Resilia; 3 holders in all
- Registered trials
- 7, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Earlier holder | 1982 to now |
| Alvogen | Acquired holder | 2021 to now |
| Resilia | Acquired holder | 2021 to now |